Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan

Abstract Introduction Molnupiravir is an oral antiviral drug that received special approval for emergency use in Japan on December 24 2021 for infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This post-marketing surveillance (PMS) is underway to investigate...

Full description

Bibliographic Details
Published in:Infectious Diseases and Therapy
Main Authors: Masahiro Kimata, Asuka Watanabe, Yukiko Yanagida, Daisuke Kinoshita, Shinichiroh Maekawa
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-03-01
Subjects:
COVID-19
Japan
Molnupiravir
Post-marketing
Safety
Online Access:https://doi.org/10.1007/s40121-023-00782-5

Internet

https://doi.org/10.1007/s40121-023-00782-5

Similar Items